Tiziana Life Sciences Share Discussion Threads

[stenick] 24/4/2019 15:57

Well that’s a question, looking at what Tils has said just recently that four such companies have sold for over 2 billion acumitavely, therefore approx a half a billion each, the fact that this seems ready to go and don’t forget foralumab “the game changer” has vast potential.
I personally would be surprised at less than £4 a share which would only be a market cap of £600million, but as we know there are billions slushing around in big pharma’s pockets and as this seems to be a good all rounder and would enhance there existing drugs maybe coupled with the “game changer” maybe 2,3,4, times that figure

[jpuff] 24/4/2019 14:44

You maybe right as the positive news of these trials leaks out to the wider market players. What do you see as a potential take out price per share? Realistic now!

[stenick] 24/4/2019 14:39

Jpuff I’m hoping I won’t be here by September as I expect this will be snapped up for a song and fast tracked to market, and I expect the song to be a classic 💥

[stenick] 24/4/2019 14:30

Lean back again.

[stenick] 24/4/2019 14:25

Still all bodes well, as in previous statements I believe Milciclib is easily manufactured and is being stockpiled.
Out of interest does anyone know who pays for the drug in these trials as it was said that these patients can continue to receive Milciclib by there relevant ethical committee?

[jpuff] 24/4/2019 13:49

These are advanced cases and are very much in the last chance saloon. The fact the drug seems to be well tolerated with a safe profile is excellent news. 80% have elected to stay on it, so I presume they are seeing benefits. We'll have a better idea end of September, but it's looking very promising.

[lean5gb] 24/4/2019 13:33

... "so far, no drug related deaths have been recorded'.That's good to know. ?

[stenick] 24/4/2019 09:53

Excellent news as expected. 80% still taking it after there session ended, some after 16months and with no drug related toxic effects and all late stage cancer patients.
This has got to be bought out surely and licensed to sell.
Seems such a versatile drug that will work alongside other drugs. Shame the market cap was destroyed by an article comparing it to other companies, no comparison surely or am I missing something here.

[jpuff] 24/4/2019 08:14

Tiziana Life Sciences PLC Interim Clinical DataSource: UK Regulatory (RNS & others)TIDMTILSRNS Number : 8676WTiziana Life Sciences PLC24 April 2019("Tiziana" or the "Company")Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients- 80% of patients who completed treatment within the trial's timeframe requested to continue treatment under compassionate use - Independent Data Monitoring Committee finds no unexpected signs or signals of toxicity - Top line data expected Q3 2019 New York/London, 24 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced results from the interim safety reviewconducted by the Independent Data Monitoring Committee (IDMC) on March 21, 2019. The IDMC reviewed safety data from patients as of February 26, 2019, and concluded that the administration of milciclib to patients with advanced hepatocellular carcinoma (HCC) was not associated with unexpected signs or signals of toxicity. Additionally, a number of patients are continuing with treatment under compassionate use. Topline data from this multi-center trial is expected to be available by the end of Q3 2019.Tiziana's Phase 2a clinical trial is a single-arm, repeated-dose (100 mg once daily; 4 days on/3 days off every 4 weeks defining each cycle), 6-month duration study to evaluate the safety, tolerability and anti-tumor activity of milciclib in Sorafenib-refractory or intolerant patients with unresectable or metastatic advanced HCC, the most common form of liver cancer. Enrollment of 31 patients in Italy, Greece, and Israel was completed on November 30, 2018.The IDMC evaluated data from 28 out of the 31 patients who were evaluable. As of April 16, 2019, a total of 10 out of 27 patients have completed the study per protocol (6 cycles, 6 months). Four patients are still under treatment, while 3 are in cycle 6 and 1 is in cycle 5. Eight out of the 10 patients who completed treatment initially expressed interest to continue with treatment. Seven of these 8 patients were approved to continue with treatment under compassionate use by their respective Ethical Committees.Three of the patients under compassionate use have completed 9, 13, and 16 months of treatment with milciclib. The other 4 patients are continuing with treatment.So far, no drug-related deaths have been recorded. Overall, the treatment with milciclib is well-tolerated with manageable drug-related toxicities. These safety and clinical activity are consistent with the earlier reported long-term safety and clinical activity of milciclib in thymic carcinoma, thymoma(1) and other solid cancers(2) ."Demonstration of safety and clinical activity is important milestone to move forward with strategic options for further clinical development of milciclib either as a single agent or in combination with one of the FDA approved drugs for treatment of HCC patients," said Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences. We previously reported data from preclinical studies demonstrating that milciclib produced pronounced synergistic anti-HCC activity in combination with any one of the FDA approved drugs such as sorafenib (Nexavar(R)), regorafenib (Stivarga(R)), and lenvatinib (Lenvima(R))(3) ."This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.For further enquiries:Tiziana Life Sciences plc [phone]Gabriele Cerrone, Chairman and founder Cairn Financial Advisers LLP (Nominated adviser) [phone] Liam Murray / Jo Turner Stockdale Securities Limited (Broker) Andy Crossley / Antonio Bossi [phone] Cited References1. Besse, B,, Garassino, M,, Rajan, A., Novello, S.,Mazieres, J., Weiss, G., Kocs, D., Barnett, J, Davite, C, Crivori, P and G. Giaccone. Efficacy of

[stenick] 11/4/2019 19:21

Ya need a sense of humour on aim.

[jpuff] 11/4/2019 18:49

Me, made me chuckle

[stenick] 11/4/2019 17:24

Who voted that up Lol

[stenick] 11/4/2019 16:14

Now leans got in cheap it’s all stopped Lol

[jpuff] 11/4/2019 16:08

Ridiculous spread 48-58p !

[lean5gb] 11/4/2019 14:17

My post explaining how the low number trades are market maker signs, and got a 'thumbs down' for my thoughts. Whoever it was, doesn't like the fact that i was correct in stating it. My intentions here are honourable, I can assure you.

[lean5gb] 11/4/2019 14:12

I can only apologise asmo, as I scanned through the premium forum and got it wrong.

[asmodeus] 11/4/2019 10:42

It wasn't me, Lean. I don't even know how or where I would signal a "thumbs down" ! And whosew argument are you requesting?

[lean5gb] 11/4/2019 01:41

I'd love to hear your argument, whoever gave me a 'thumbs down' (premiun user) I can only summise it came from asmodeus

[lean5gb] 10/4/2019 17:38

Yes..... Fingers crossed... On a positve note, the mm's needing shares, predicting good times ahead regarding the sp?So a retrace temporarily for consolidation.

[jpuff] 10/4/2019 11:20

Ok, well we shall see what happens but I personally can't see that occurring fingers crossed!

[lean5gb] 10/4/2019 10:45

The 3 signifies the mm's, or one of them needing to load up with shares, asking for the price to be reduced 30% to do so, but, sometimes it doesnt happen.. That's just my take on it. The low trades are significant, but its all 'smoke n mirrors' in aim.

[jpuff] 10/4/2019 09:26

I've noticed tiny trades like the 3 here that you mentioned. I've also noticed it or similar in many other shares too. What's that all about? A secret signal to other or what?

[asmodeus] 10/4/2019 07:32

Beware any poster calling himself sphere employee.

[lean5gb] 10/4/2019 07:30

Yes quite true Sten. Im quickly closing in on retirement, and since my big loss with Percys shysters, i tend to get my pocket money from mid cap shares now,. This company looks better set up, but I'll pass and spectate. I noticed a 3 trade yesterday.... Hmmmmm... Take care peeps.

[stenick] 10/4/2019 07:08

Hi lean, seems along time ago now, my memory is a bit hazy now Lol.